Autolus Therapeutics (AUTL) Q1 2026 earnings summary

Executive summary

• Q1 2026 net product revenue reached $26.2 million, up from $9.0 million year-over-year, driven by strong AUCATZYL launches in the US and UK, with positive physician feedback and expanding patient demographics.

• Achieved first positive gross margin for the ALL business, supported by increased volume, operational improvements, and cost reduction initiatives.

• Strategic operational efficiency plan included a 13% workforce reduction, expected to save $15 million annually starting in 2027.

• Pipeline progress includes ongoing pivotal and early-stage trials in pediatric ALL, lupus nephritis, progressive MS, and light-chain amyloidosis, with key data readouts expected through 2028.

Financial highlights

• Net product revenue for Q1 2026 was $26.2 million, up from $9.0 million in Q1 2025, reflecting US growth and initial UK sales.

• Positive gross margin of $1.6 million in Q1 2026, compared to losses in prior quarters.

• Cost of sales increased to $24.6 million, mainly due to higher sales volume and inventory-related costs.

• R&D expenses decreased to $21.2 million, while SG&A expenses rose to $39.9 million, partly due to one-time restructuring costs.

• Net loss for Q1 2026 was $71.6 million, or $(0.27) per share, slightly higher than $70.2 million, or $(0.26) per share, in Q1 2025.

• Cash, cash equivalents, and marketable securities totaled $229.4 million at March 31, 2026, down from $300.7 million at year-end 2025.

Outlook and guidance

• Full-year 2026 AUCATZYL net product revenue guidance remains $120 million–$135 million, unchanged from prior forecasts.

• Continued positive gross margin anticipated for 2026, with peak gross margin targeted at 65%-70%.

• Cash runway projected into Q4 2027 based on current plans and revenue expectations.

• Profitability for the ALL business anticipated in 2028, with company-wide profitability dependent on reinvestment rates.

• No EU product revenue expected in 2026 as commercial launch in Germany and other EU countries is on hold.